Bilgi Gungor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bilgi Gungor has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Mueller
Division of Experimental Pathology, Institute of Pathology, University of Bern, 3008 Bern, Switzerland
1 shared publication - Juliana Barreto de Albuquerque
Division of Experimental Pathology, Institute of Pathology, University of Bern, 3008 Bern, Switzerland
1 shared publication
Latest Publications
- Open Access
Tissue-Resident T Cells in Chronic Relapsing–Remitting Intestinal Disorders
Tissue-resident memory T (TRM) cells critically contribute to the rapid immunoprotection and efficient immunosurveillance against pathogens, particularly in barrier tissues, but also during anti-tumor responses. However, the involvement of TRM cells also in the induction and exacerbation of immunopathologies, notably in chronically relapsing auto-inflammatory disorders, is becoming increasingly recognized as a critical factor. Thus, TRM cells may also represent an attractive target in the management of chronic (auto-) inflammatory disorders, including multiple sclerosis, rheumatoid arthritis, celiac disease and inflammatory bowel diseases. In this review, we focus on current concepts of TRM cell biology, particularly in the intestine, and discuss recent findings on their involvement in chronic relapsing–remitting inflammatory disorders. Potential therapeutic strategies to interfere with these TRM cell-mediated immunopathologies are discussed.
Open AccessTissue-Resident T Cells in Chronic Relapsing–Remitting Intestinal Disorders
Tissue-resident memory T (TRM) cells critically contribute to the rapid immunoprotection and efficient immunosurveillance against pathogens, particularly in barrier tissues, but also during anti-tumor responses. However, the involvement of TRM cells also in the induction and exacerbation of immunopathologies, notably in chronically relapsing auto-inflammatory disorders, is becoming increasingly recognized as a critical factor. Thus, TRM cells may also represent an attractive target in the management of chronic (auto-) inflammatory disorders, including multiple sclerosis, rheumatoid arthritis, celiac disease and inflammatory bowel diseases. In this review, we focus on current concepts of TRM cell biology, particularly in the intestine, and discuss recent findings on their involvement in chronic relapsing–remitting inflammatory disorders. Potential therapeutic strategies to interfere with these TRM cell-mediated immunopathologies are discussed.